February 20, 2025 07:35 AM EST
Deals
China
Pharma

As­traZeneca buys Fi­bro­Gen’s Chi­na unit for lo­cal con­trol of ane­mia drug

Kyle LaHucik

Senior Reporter

As­traZeneca is fur­ther­ing its pres­ence in Chi­na by gain­ing com­plete con­trol of Fi­bro­Gen’s sub­sidiary in the coun­try for about $160 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

FDA says Ozem­pic, We­govy short­age is over

Kevin Tang's Con­cen­tra tries to dis­rupt pro­posed Ace­lyrin-Alu­mis merg­er

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Mer­ck KGaA tees up changes to lead­er­ship team; Ex-CVS Health CEO joins Ther­mo Fish­er’s board

Roche no longer wants to be where ‘DNA se­quenc­ing goes to die’

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times